EUVIMEDEUVIMED entdecken
Open Access

Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast

Nicholas S Teran iD, Cole S Hudson iD, Kady Phe iD, Yunting Wang, Yang Zhang iD, Hua Chen iD, Masayuki Nigo, Vincent H Tam iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Nicholas S Teran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Cyclopropanes, Sulfides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vancomycin ranks among the most utilized antimicrobial agents in the treatment of serious β-lactam–resistant gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in preclinical models with adjuvant montelukast. The purpose of the study was to ascertain if montelukast was associated with a reduction in the prevalence of vancomycin-associated AKI.

Methods

This retrospective cohort study examined adult patients who received intravenous vancomycin between January 2020 and January 2024. The RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease) were employed in identifying cases of AKI. Additionally, a preclinical vancomycin-associated nephrotoxicity model was established to provide insights into possible renal protective mechanisms.

Results

Patients receiving montelukast (n = 110) were compared with controls (n = 330), of which AKI was observed in 3 (2.7%) vs 35 (10.6%), respectively (P = .01). A multivariate logistic regression analysis revealed that weight (odds ratio [OR], 1.02; 95% CI, 1.006–1.03; P = .005) and intensive care unit admission (OR, 6.88; 95% CI, 2.96–18.8; P < .001) were independently associated with AKI, while montelukast (OR, 0.26; 95% CI, .06–.77; P = .03) and male gender were protective (OR, 0.41; 95% CI, .19–.85; P = .02). Our in vitro model also revealed that adjuvant montelukast can reduce injury to proximal tubule cells through activation of the p62/KEAP-1/HO-1 antioxidant pathway.

Conclusions

Our study suggests that montelukast during vancomycin therapy may be protective against AKI, which may reduce patient harm and hospitalization costs. Further studies are warranted to validate our findings prospectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinAcute Kidney InjuryCyclopropanesSulfidesAnti-Bacterial AgentsQuinolinesAcetatesHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

adjuvant therapyglycopeptidegram positivenephroprotectionnephrotoxicity

Substanzen

montelukastVancomycinCyclopropanesSulfidesAnti-Bacterial AgentsQuinolinesAcetates

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston.
  • Department of Pharmacy, Baylor St Luke's Medical Center.
  • Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston.
  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston.
  • Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Texas Medical Center.

ORCID-Profile: Nicholas S Teran, Cole S Hudson, Kady Phe, Yang Zhang, Hua Chen, Vincent H Tam

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Teran, N. S., Hudson, C. S., Phe, K., Wang, Y., Zhang, Y., Chen, H., Nigo, M., & Tam, V. H. (2025). Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf027

Vancouver

Teran NS, Hudson CS, Phe K, Wang Y, Zhang Y, Chen H, et al. Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf027

BibTeX
@article{Teran2025,
  author = {Teran, Nicholas S and Hudson, Cole S and Phe, Kady and Wang, Yunting and Zhang, Yang and Chen, Hua and Nigo, Masayuki and Tam, Vincent H},
  title = {Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf027}
}
Kostenlos starten →